Galecto Inc., whose recent SEC reports identify the registrant as Damora Therapeutics, Inc. following Galecto's acquisition of privately held Damora Therapeutics in November 2025, files disclosures covering biotechnology corporate structure, governance, and equity compensation. Form 8-K reports document executive officer appointments and departures, related compensation arrangements, and changes in the registrant's independent registered public accounting firm.
Proxy materials describe board matters, executive compensation, equity-award information, pay-versus-performance data, shareholder voting items, and governance procedures. The filing record also reflects public-company reporting around Galecto/Damora corporate status and clinical-stage therapeutic development.
Galecto, Inc. director Bruno Julianne reported acquiring Common Stock through the conversion of preferred shares. On February 9, 2026, after stockholders approved the issuance of Common Stock upon conversion of Series C Non-Voting Convertible Preferred Stock, 129 shares of Series C Preferred Stock converted into 129,000 shares of Common Stock at a price of $0 per share.
After this derivative conversion, Julianne directly beneficially owned 137,032 shares of Common Stock. These securities, including the newly issued Common Stock, are subject to a lock-up agreement related to Galecto’s public offering, restricting sales or transfers for 60 days following the February 10, 2026 final prospectus supplement.
Galecto, Inc. reported that investment funds managed by Fairmount converted Series C Non-Voting Convertible Preferred Stock into common shares after stockholder approval on February 9, 2026. Fairmount Healthcare Fund II L.P. converted 5,809 Series C shares into 5,809,000 common shares, and Fairmount Healthcare Co-Invest V L.P. converted 2,904 Series C shares into 2,904,000 common shares, reflecting a 1,000-to-1 conversion ratio.
The converted shares, along with other securities held by the reporting persons, are subject to a lock-up that generally restricts sales or transfers for 60 days after the February 10, 2026 final prospectus supplement for Galecto’s public offering. The Series C Preferred Stock has no expiration date, and conversions are capped so that Fairmount and its affiliates cannot beneficially own more than 19.99% of Galecto’s outstanding common shares immediately after any conversion. Fairmount Funds Management LLC, led by managers Peter Harwin and Tomas Kiselak, is the investment manager for the converting funds and disclaims beneficial ownership except for its pecuniary interest.
Fairmount Funds Management and affiliated entities report beneficial ownership of 8,713,000 Galecto common shares, representing 19.99% of the class, based on 43,595,335 shares outstanding as of February 9, 2026.
The filing reflects automatic conversion of Series C Preferred Stock after shareholder approval. On February 9, 2026, 5,809 Series C shares held by Fund II and 2,904 Series C shares held by Co-Invest converted into 5,809,000 and 2,904,000 common shares, respectively.
Additional common shares issuable from Series B and Series C Preferred Stock are excluded from reported ownership due to a 19.99% beneficial ownership cap, which will automatically reduce to 9.99% once Fairmount and affiliates beneficially own 9.0% or less. Fund II, Co-Invest and certain individuals agreed to 60-day lock-up restrictions following the February 10, 2026 final prospectus supplement for Galecto’s public offering.
Galecto, Inc. entered into an underwriting agreement to sell 14,473,685 shares of common stock at $19.00 per share, with underwriters granted a 30‑day option to buy up to an additional 2,171,052 shares on the same terms, which was exercised in full. Net proceeds to the company from this offering are approximately $295.9 million after underwriting discounts and estimated expenses. Galecto expects these funds, together with existing cash and cash equivalents, to be sufficient to finance operations into Phase 3 development of its candidate DMR-001, although it notes this estimate depends on assumptions that may prove incorrect. The shares are being issued under an automatic shelf registration statement on Form S-3, with the offering expected to close on February 12, 2026.
Galecto, Inc. is offering 14,473,685 shares of common stock at $19.00 per share in an underwritten public offering. The company has granted underwriters a 30‑day option to buy up to 2,171,052 additional shares.
Galecto expects net proceeds of about $257.2 million, or $295.9 million if the option is fully exercised, to fund preclinical studies, clinical trials and manufacturing for its antibody programs, broader R&D, working capital and general corporate purposes, and potentially future in‑licensing or acquisitions. Based on its current plan, this cash plus existing funds should finance operations into Phase 3 development of lead candidate DMR‑001 but not through regulatory approval.
The company highlights immediate and substantial dilution: at a $19.00 offering price, investors face $11.68 per share of dilution relative to the pro forma as‑adjusted net tangible book value of $7.32 per share. Pro forma as‑adjusted shares outstanding would be 58,061,568 as of September 30, 2025. Galecto remains a clinical‑stage biopharmaceutical company focused on hematological malignancies, including ET, MF and AML.
Galecto, Inc. is conducting an underwritten primary offering of common stock and Series C non-voting convertible preferred stock under its shelf registration. The Series C shares are convertible into common stock at a 1,000-to-1 ratio, subject to a holder‑set ownership cap between 0% and 19.99% of outstanding common shares.
Galecto is a biopharmaceutical company focused on therapies for hematological cancers, including new candidates targeting myeloproliferative neoplasms and acute myeloid leukemia gained through recent asset acquisitions. The company plans to use net proceeds mainly for preclinical studies, clinical trials, manufacturing for its antibody programs, broader research and development, working capital, and general corporate purposes.
Galecto, Inc. is conducting an underwritten primary offering of common stock and Series C non-voting convertible preferred stock under its shelf registration. The Series C shares are convertible into common stock at a 1,000-to-1 ratio, subject to a holder‑set ownership cap between 0% and 19.99% of outstanding common shares.
Galecto is a biopharmaceutical company focused on therapies for hematological cancers, including new candidates targeting myeloproliferative neoplasms and acute myeloid leukemia gained through recent asset acquisitions. The company plans to use net proceeds mainly for preclinical studies, clinical trials, manufacturing for its antibody programs, broader research and development, working capital, and general corporate purposes.
Galecto, Inc. has filed an automatic shelf registration statement on Form S-3 as a well-known seasoned issuer, allowing it to offer common stock, preferred stock, debt securities, warrants and units from time to time using prospectus supplements.
The filing details Galecto’s strategic shift into hematologic cancers following its stock-for-stock acquisition of Damora Therapeutics and assumption of the Paragon Option Agreement, adding three mutCALR-targeting antibody programs (DMR-001, DMR-002, DMR-003) and the AML candidate GB3226. Galecto plans IND filings for GB3226 in the first quarter of 2026 and for DMR-001, DMR-002 and DMR-003 between 2026 and 2027.
Galecto also highlights a recently completed approximately $285 million private placement of Series C Preferred Stock and an increase in authorized common shares to 500 million, supporting development of its expanded pipeline in myeloproliferative neoplasms and acute myeloid leukemia.
Galecto, Inc. has filed an automatic shelf registration statement on Form S-3 as a well-known seasoned issuer, allowing it to offer common stock, preferred stock, debt securities, warrants and units from time to time using prospectus supplements.
The filing details Galecto’s strategic shift into hematologic cancers following its stock-for-stock acquisition of Damora Therapeutics and assumption of the Paragon Option Agreement, adding three mutCALR-targeting antibody programs (DMR-001, DMR-002, DMR-003) and the AML candidate GB3226. Galecto plans IND filings for GB3226 in the first quarter of 2026 and for DMR-001, DMR-002 and DMR-003 between 2026 and 2027.
Galecto also highlights a recently completed approximately $285 million private placement of Series C Preferred Stock and an increase in authorized common shares to 500 million, supporting development of its expanded pipeline in myeloproliferative neoplasms and acute myeloid leukemia.
Galecto, Inc. announced major corporate changes centered on leadership and capital structure. The board determined that, effective February 10, 2026, Hans T. Schambye will step down as Chief Executive Officer and President and resign from the board, with no disagreement cited over operations or policies. Subject to a separation agreement, he will receive benefits under his retention agreement and the Executive Separation Benefits Plan, including lump-sum severance and full acceleration of all outstanding equity awards.
The board appointed current Chief Operating Officer Sherwin Sattarzadeh as interim principal executive officer, with his existing offer letter continuing to govern his employment. At a February 9, 2026 special meeting, stockholders approved the issuance of common shares upon conversion of Series B and Series C preferred stock, an increase in authorized common shares from 300,000,000 to 500,000,000, a redomestication from Delaware to the Cayman Islands, and new 2026 equity incentive and employee stock purchase plans. Following automatic conversion of 42,005 shares of Series C preferred into 42,005,000 common shares, the company had approximately 43.6 million common shares outstanding as of February 9, 2026.
Galecto, Inc. announced major corporate changes centered on leadership and capital structure. The board determined that, effective February 10, 2026, Hans T. Schambye will step down as Chief Executive Officer and President and resign from the board, with no disagreement cited over operations or policies. Subject to a separation agreement, he will receive benefits under his retention agreement and the Executive Separation Benefits Plan, including lump-sum severance and full acceleration of all outstanding equity awards.
The board appointed current Chief Operating Officer Sherwin Sattarzadeh as interim principal executive officer, with his existing offer letter continuing to govern his employment. At a February 9, 2026 special meeting, stockholders approved the issuance of common shares upon conversion of Series B and Series C preferred stock, an increase in authorized common shares from 300,000,000 to 500,000,000, a redomestication from Delaware to the Cayman Islands, and new 2026 equity incentive and employee stock purchase plans. Following automatic conversion of 42,005 shares of Series C preferred into 42,005,000 common shares, the company had approximately 43.6 million common shares outstanding as of February 9, 2026.
Galecto, Inc. reported new equity awards to its Chief Operating Officer, Sherwin Sattarzadeh. On January 5, 2026, he received 190,376 shares of common stock in the form of restricted stock units, granted at a price of $0 per share. These RSUs vest 25% on each anniversary of the grant date over four years, so the award is spread out to encourage continued service.
On the same date, he was also granted a stock option covering 444,209 shares of common stock with an exercise price of $21.82 per share. This option vests 25% on January 5, 2027 and then in equal monthly installments through January 5, 2030, again conditioned on his continued service to Galecto.
Galecto, Inc. filed an initial insider ownership report for its Chief Operating Officer. The Form 3 identifies Sherwin Sattarzadeh as the company’s Chief Operating Officer and a reporting person under insider ownership rules. The filing states in the remarks that no securities are beneficially owned, meaning the officer reported holding no Galecto, Inc. common stock or derivative securities at the time of this initial statement.